July 2026 Research Update

This month added a clearer high-level picture of FRDA drug research: across published human studies up to mid-2025, omaveloxolone is the only medicine that showed a statistically significant improvement on a standard movement and function scale, while results for other medicines were not consistently positive. [1]

In the meta-analysis, researchers combined results from 16 studies (351 participants total) and focused on how people scored on the modified Friedreich Ataxia Rating Scale (mFARS), a measure of day-to-day movement and coordination problems. Omaveloxolone showed an average mFARS improvement compared with control, and the overall rate of side effects reported across medicines was similar to control, although the authors described the overall certainty of evidence as low because the studies were small and often short. [1]

For patients, this does not introduce a new treatment option by itself, but it helps clarify where the strongest published human evidence sits right now: omaveloxolone is the one medication that has shown a measurable improvement on a widely used FRDA rating scale when results are pooled. It also highlights what remains uncertain, including how confident we can be in smaller, shorter trials and how well results from different drugs compare when studies use different designs and outcome measures. [1]

This month, experimental FRDA research mostly pointed in the same direction: multiple approaches in cells and animals reported improvements in FRDA-related biology and function, but all of this evidence is still preclinical. The common message is that researchers are testing different ways to reduce damage from low frataxin, including changing oxygen handling, changing fat-like signaling molecules in cells, and changing iron handling. [2] [3] [4] [5]

One mouse study tested a two-drug combination, GBT601 plus PT2399, designed to create a controlled "low oxygen" state in the body and brain. In a Friedreich ataxia mouse model, the study reported preserved motor performance on tasks like coordination and strength, with effects described as similar to breathing a low-oxygen mixture used as a benchmark in the experiments. [2]

Another set of experiments, using FRDA patient-derived cells and an FRDA mouse model, focused on enzymes involved in sphingolipid metabolism (fat-like molecules that help regulate cell stress responses). Small molecules aimed at SPHK1 (K6PC-5) and LPP1 (XY-14), and also partial LPP1 gene knockdown, increased frataxin protein and improved several mitochondrial and oxidative stress measures, although frataxin did not return fully to control levels in the mouse work. [3]

In patient-derived sensory neurons grown from three iPSC lines, sulforaphane was compared with omaveloxolone and dimethyl fumarate. Sulforaphane produced more consistent improvements across the lines in cell survival, frataxin-related measures, and markers linked to oxidative stress and inflammation, while responses to omaveloxolone and dimethyl fumarate varied by cell line. [4]

A fruit fly model with FRDA-like genetic changes reported that reducing intestinal iron uptake nearly doubled survival and improved movement, and the study described glial cells (support cells in the brain) as early iron-sensitive targets. This suggests that, at least in this model, gut iron absorption can influence how much iron builds up in the nervous system and how severe disease features become. [5]

For patients and caregivers, these studies mainly matter as a snapshot of where research is heading rather than evidence of what will work in people. They help clarify which biological pathways are being actively pursued (oxygen handling, sphingolipid signaling, and iron handling) and they add early clues that different genetic backgrounds might respond differently in lab models. What remains uncertain is whether any of these approaches will be safe and effective in humans, because cell, fly, and mouse results often do not predict real-world benefits. [2] [3] [4] [5]

This month included a large survey that makes the practical side of living with ataxia more visible: getting to a specialist center is not just about the diagnosis, but also about travel burden and how physically able someone is to keep attending. The study also reported that the mix of diagnoses seen in specialist ataxia centers differed across the UK, Italy, and Germany, with Friedreich ataxia more represented among attendees in Italy and Germany than in the UK. [6]

Across 550 people with ataxia, shorter travel time, fewer non-ataxia health conditions, and being employed were linked to being referred to or attending a Specialist Ataxia Centre. The survey also found that greater mobility impairment was linked to discontinuing attendance, which fits with the idea that progressing disability can itself become a barrier to staying connected with specialized care. [6]

For families, this evidence may matter now because it describes common, real-world barriers to specialist follow-up, especially as mobility becomes more limited. It does not test an intervention, but it helps clarify which factors are linked to getting and keeping access, which could influence how future services are designed and evaluated (for example, options that reduce travel burden). What remains uncertain is how much these patterns reflect the healthcare systems in each country versus who chose to respond to the survey. [6]

This month had one case report that separates blood measures from nervous system outcomes: in a child with FRDA who needed a stem cell transplant for leukemia, blood frataxin and related blood genetic markers returned to normal after transplant, but the neurological course still worsened over time. This adds a concrete example that improving blood frataxin markers alone may not reflect what is happening in the brain and nerves. [7]

Over 10 years of follow-up, the patient remained in leukemia remission and heart muscle thickening declined, while ataxia-related function worsened based on FRDA rating measures reported in the case. The report noted no major transplant complications such as graft-versus-host disease, and it described later development of diabetes and sleep apnea. [7]

For patients, this is not evidence for a new FRDA treatment, because it is a single person treated for a different life-threatening condition. It does help clarify an important research question: blood-based improvements (including frataxin levels in blood cells) may not track with neurological change, which matters when interpreting biomarkers in future studies. What remains uncertain is whether different approaches that raise frataxin in nervous system tissue would show a different outcome. [7]